Article Text

Download PDFPDF
Respiratory syncytial virus vaccination in pregnancy is not effective enough at reducing infant infections
  1. Carla Wesley,
  2. Lucinda C Winckworth
  1. Neonatal Unit, Royal Hampshire County Hospital, Winchester SO22 5DG, UK
  1. Correspondence to Dr Lucinda C Winckworth, Neonatal Unit, Royal Hampshire County Hospital, Winchester SO22 5DG, UK; lucinda.winckworth{at}hhft.nhs.uk

Statistics from Altmetric.com

Review ofMadhi SA, Polack F, Piedra P et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020;383:426–39.

Design: Randomised placebo controlled trial.

Allocation: 1:1 (first global season) and 2:1 ratio (subsequent seasons) vaccine to placebo.

Blinding: Observer blind.

Setting: Multinational (87 sites in 11 countries).

Participants: 4636 healthy pregnant women aged 18–40 years between 28 and 36 weeks gestation. Exclusion criteria were essentially any mother with any underlying health condition or on any medication.

Intervention: Women were randomised to receive either single dose of intramuscular respiratory syncytial virus (RSV) F-protein vaccine or placebo vaccine.

Outcomes: Primary outcome was vaccine efficacy (VE) of prevention of medically significant RSV lower respiratory tract infection (MS-RSV LRTI) …

View Full Text

Footnotes

  • Contributors CW wrote the first draft of the abstract and commentary, LCW edited and added to both.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.